MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the initiation of VALUE, a global, pivotal Phase III trial evaluating ...
These early data are reassuring, but there are many questions yet to be explored in the upcoming pivotal trial, Nancy ...
In an editorial, J. Mocco, MD, of Mount Sinai Health System in New York City, characterized the DISTAL and ESCAPE-MeVO cohorts as being older and having higher baseline disability, which may have ...
PhaseV, a pioneer in software and machine learning (ML) for clinical trial optimization, announced today it has entered a strategic partnership with Alimentiv Inc., a global GI (gastrointestinal) ...
PHILADELPHIA, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is also pleased to announce that its phase 2 clinical study (SKNJCT-003) which is ...
Satellos Bioscience Inc. ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today ...
Pfizer Inc. today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide ...
Real world data (RWD), which is data from actual patient treatments, provides valuable information on safety and effectiveness of innovative ...
Since 2018, the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH), a founding member of the Mass General Brigham healthcare system, has been working with national and ...
INGELHEIM, Germany I 10, 2025 I Boehringer Ingelheim announced today that the FIBRONEERâ„¢-ILD trial met its primary endpoint, which was the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback